DNA methylation signatures in cord blood associated with maternal gestational weight gain: results from the ALSPAC cohort

Eva Morales¹,²,³,⁴, Alexandra Groom⁵,⁶, Debbie A Lawlor⁵,⁶ and Caroline L Relton¹,⁵,⁶*  

Abstract  

Background: Epigenetic changes could mediate the association of maternal pre-pregnancy body mass index (BMI) and gestational weight gain (GWG) with adverse offspring outcomes. However, studies in humans are lacking. Here, we examined the association of maternal pre-pregnancy BMI and GWG in different periods of pregnancy with cytosine-guanine (CpG) dinucleotide site methylation differences in newborn cord blood DNA from 88 participants in the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort using the Illumina GoldenGate Panel I. Pyrosequencing was used for validation of the top associated locus and for replication in 170 non-overlapping mother-offspring pairs from the ALSPAC cohort.  

Results: After correction for multiple testing greater GWG in early pregnancy (between 0 to 18 weeks of gestation) was associated with increased DNA methylation levels in four CpG sites at MMP7, KCNK4, TRPM5 and NFKB1 genes (difference in methylation >5% per 400 g/week greater GWG) (q values 0.023 -0.065). Pre-pregnancy BMI and GWG in mid- or late pregnancy were not associated with differential DNA methylation at any CpG site. Pyrosequencing showed that greater GWG in early pregnancy was associated with increased DNA methylation levels at the top associated CpG site at MMP7, although association did not reach statistical significance (p = 0.302). Greater GWG in mid- (p = 0.167) and late-pregnancy (p = 0.037) were also associated with increased DNA methylation levels at the MMP7 CpG site. In addition, newborns of mothers who exceeded the IoM-recommended GWG had higher DNA methylation levels at the MMP7 CpG site than those of mothers with IoM-recommended GWG (p = 0.080). We failed to replicate findings.  

Conclusions: Greater GWG in early pregnancy was associated with increased methylation at CpG sites at MMP7, KCNK4, TRPM5 and NFKB1 genes in offspring cord blood DNA. The specific association of GWG in early pregnancy with the top associated CpG site at MMP7 was not validated using Pyrosequencing and it did not replicate. However, given the potential functional relevance of the four identified loci, we advocate further exploration of them in larger studies.  

Keywords: DNA methylation, Epigenetics, Gestational weight gain

Background  

Greater maternal pre- or early- pregnancy body mass index (BMI) and gestational weight gain (GWG) have been shown to be associated with health outcomes in offspring, including increased birth weight [1,2], impaired cognitive development and behavioral problems [3,4], increased adiposity and adverse cardiometabolic traits [5-13]. The biological mechanisms underpinning these associations remain elusive. Potential mechanisms may include genetic factors, shared postnatal environment, as well as intrauterine metabolic programming, possibly through epigenetic mechanisms [13,14]. With respect to potential intrauterine mechanisms the main exposure is greater maternal adiposity during pregnancy, and thus one might expect a specific association of GWG in early pregnancy, when the contribution of maternal fat deposition is greater than that of fetal weight.
or other GWG contributions in later periods, and little or no association of GWG in mid or later pregnancy with offspring outcomes [8,14]. In relation to offspring adiposity and cardiometabolic outcomes results from the cohort used in this study support this expectation [8].

To our knowledge only one study in humans has examined the association of maternal pregnancy adiposity with offspring DNA methylation patterns. In that study, cord blood white cell DNA methylation was compared between 25 offspring born before their mothers had undergone bypass surgery for severe obesity with 25 matched siblings born after marked weight loss by their mothers following bypass surgery, using the Illumina HumanMethylation450 BeadChip array [15,16]. Altered methylation and gene expression profiles of genes with known glucose-metabolic and inflammatory related functions were identified between those offspring born after their mothers surgery compared to those born before [15,16]. Recently a study conducted in African-American population has reported maternal pre-pregnancy BMI to be associated with offspring cord blood DNA methylation levels of the CpG sites in genes involved in a broad array of chronic diseases including cancer and cardiovascular diseases [17]. However, whether similar associations would be found between maternal GWG in humans is currently unknown. Nonetheless evidence from animal models strongly supports an effect of greater maternal pregnancy adiposity on offspring epigenome. For example, gene expression and DNA methylation patterns at loci involved in adipocyte commitment have been shown to be perturbed in rodent models of maternal obesity and overfeeding during pregnancy [18,19].

We hypothesize that maternal pre-pregnancy BMI and GWG, specifically in early pregnancy, could influence risk of adverse health outcomes in offspring by inducing epigenetic changes. Thus, we aimed to examine whether maternal pre-pregnancy BMI and GWG in different periods of pregnancy were associated with epigenetic marks in newborns, in terms of gene-specific cord blood DNA methylation, and to compare the early pregnancy GWG associations with mid- and late-pregnancy GWG to test whether there was any evidence of specific early pregnancy associations. Our analyses were undertaking in a discovery sample and then in a replication sample, both taken from a large, longitudinal UK cohort of mothers and their offspring.

Method

Discovery and validation study

Study population

Data were available from participants in the Avon Longitudinal Study of Parents and Children (ALSPAC), a prospective, population-based mother-child cohort study that recruited over 14 000 pregnant women resident in Avon, UK, between 1991 and 1992 (http://www.alspac.bristol.ac.uk) [20,21]. A subset of 96 children from the ALSPAC cohort was selected for analysis of DNA methylation at Cytosine-Guanine (CpG) dinucleotide sites in DNA extracted from cord blood samples. Samples used in this study had been analyzed as part of a study of maternal exposure to paracetamol, as described in previous literature [22], and were broadly representative of the ASPAC cohort. Of the 96 mother-offspring pairs with methylation data available, complete data on maternal pre-pregnancy BMI, GWG and potential confounders were available for 88 pairs.

Maternal pre-pregnancy BMI and GWG

Six trained research midwives abstracted data from obstetric medical records for the entire ALSPAC cohort. Obstetric data abstractions included every measurement of weight entered into the medical records and the corresponding gestational age and date. All pregnancy weight measurements (median number of repeat measurements per woman, 10; range, 1, 17) were used to develop a linear spline multilevel model (with 2 levels: woman and measurement occasion) relating gestational age to weight. Using the entire cohort of women with term pregnancies (≥37 weeks of gestation) fractional polynomial curves were fitted to the data to obtain the average shape of the trajectories of GWG with gestational age (for full statistical methodological details see [8]). These were used to determine the approximate positions of knots (indicating changes in slope) in linear spline random effects models with GWG as outcome and gestational age in weeks as the exposure. The knots produced from the modelling resulted in 4 variables: Pre-pregnancy weight (kg), change in weight between 0 and 18 weeks (kg/week), change in weight between 19 and 28 weeks (kg/week), and change in weight between 29 weeks and birth (kg/week). Pre-pregnancy body mass index (BMI) (kg/m²) was based on the mother’s self-reported weight before pregnancy and maternal report of height at their first questionnaire assessment (~12-18 weeks gestation) (results were identical for predicted pre-pregnancy weight with the use of multilevel models) [8]. To allocate women to Institute of Medicine (IoM) GWG categories (less than recommended, recommended, or more than recommended), we used weight measurements from the obstetric notes and subtracted the first from the last weight measurement in pregnancy to derive absolute weight gain [23].

Cord blood DNA methylation analysis using Illumina Golden Gate

DNA extracted from cord blood was used for DNA methylation analysis. Site-specific CpG methylation was analysed using bisulphite treated DNA (EZ-96 DNA
Methylation Gold Kit, Zymo Research) using the the GoldenGate Cancer Panel I Array (Illumina Inc, USA) and the GoldenGate Assay Kit with UDG on the Sentrix Universal-96 Array matrix v7A. This panel spans 1,505 CpG sites selected from 807 genes. Arrays were imaged using a BeadArray scanner and image processing and intensity data extracted using Illumina BeadStudio v3.2, methylation module v3.2.5 custom software. Methylation levels (beta values, \( \beta \)) at a given CpG site were estimated as the ratio of signal intensity of the methylated alleles to the sum of methylated and unmethylated intensity signals of the alleles: \( \beta = M/(U + M) \), where M was the fluorescence level of the methylation probe and U was the fluorescence level of the unmethylated probe. The beta values vary from 0 (no methylation) to 1 (100% methylation). Samples were run across four different PCR plates.

Other variables
Based on previous knowledge, the following were considered a priori potential confounding factors because of their possible associations with either maternal pre-pregnancy BMI or GWG and DNA methylation levels: child’s sex and ethnic background, mode of delivery, maternal age at child’s birth, parity, maternal smoking in pregnancy and occupation. Child’s sex, maternal age, parity (0 or 1+) and mode of delivery (cesarean or vaginal delivery), and child’s ethnic background (white or non-white) were obtained from the obstetric records. Maternal smoking and occupational (of both the mother and her partner) were reported by the mother in a study questionnaire administered at mean 18 weeks gestation; with data on smoking also reported in subsequent questionnaires administered during pregnancy. Maternal smoking in pregnancy was categorized as no versus yes. Highest parental occupation was used to allocate the children to family social class groups according to the 1991 British Office of Population and Census Statistics classification [24] (with the higher class of either parent where these differed being used); this was collapsed into a binary variable of manual versus non-manual in this study.

Validation study
A PyroMark MD Pyrosequencing System (Qiagen) was used for the validation of the top associated locus (MMP7_E59). This quantifies DNA methylation in a sequencing-by-synthesis manner providing precise methylation levels of several CpG positions in close proximity [25]. The DNA segment harboring the region of MMP7 amplified for this purpose and analyzed consisted of the sequence 5’- AGGCTGAGAAGCTATATAAATTTCTG CAGTCACTAGCAGAAAAACACCCAATAATCAACCATA CGACTCACCCGTGCTGTGCTGTGCTGTGCTGTGCT GCCTGGCAGCTGCTGGCAGCTGCTGGCAGCTGCTGGC GGGAGGCATGAGTGAGCTACAGTGGAAC-3’. As indicated in italics, we analyzed three CpG sites overall. The one referring to CpG probe site MMP7_E59 is highlighted in bold. The forward PCR and reverse PCR, and sequencing primers were AGGTTGAGAAGTTATA TAAAA, ATCCCCACTATAACCTCACC, and AATTAAT TATAGGTTTAAAGA, respectively. Briefly, bisulfite conversion of genomic DNA was performed using EZ DNA Methylation Gold™ kit (Zymo Research) following the manufacturer’s protocol. Quantitative bisulphite Pyrosequencing (Qiagen, UK) with Pyro Q-CpG™ Software (version 1.0.6.) was subsequently used to determine the percentage methylation at individual CpG sites. 1ug of DNA was bisulfite modified. Bisulfite treated DNA was added to the first PCR reaction with 12.5 μl Hot Star Taq mastermix (Qiagen) and optimised primer concentrations and annealing temperature. PCR cycling conditions were: 95 degrees C for 15 min, 50 cycles of 95 for 15 secs, 45 degrees C for 30secs, 72 for 15 secs, 72 for 5 min, and 4 for hold/storage. Assays were assessed for amplification bias and reliability as described previously [26,27]. Zero and 100% in vitro methylated controls were run routinely alongside samples as internal controls, as well as, negative controls consisting of DNA free wells. Zero and 100% in vitro methylation internal controls showed good correlation (\( R^2 = 0.99 \)). Two independent replicates per sample were processed on separate runs, giving good correlation (\( R^2 \) between 0.658 and 0.847).

Replication study
The same Pyrosequencing assay used during the validation study of the top associated locus (MMP7_E59) was used to analyze 192 non-overlapping mother-offspring pairs randomly selected from the 2,183 ALSPAC cohort participants with cord blood DNA available and who were not included in the discovery study. Of these 192 pairs 170 (88%) could be successfully characterized.

Statistical analysis
In the discovery study mixed linear regression models were fitted to estimate the association of pre-pregnancy BMI and GWG in different periods of pregnancy with DNA methylation in offspring cord blood, regressing the methylation status at each CpG site quantified by the Illumina beta value (dependent variable) against maternal pre-pregnancy BMI or GWG (independent variables). Maternal pre-pregnancy BMI and GWG were scaled to be clinically meaningful, examining the variation in CpG site DNA methylation per 1 SD change of maternal pre-pregnancy BMI and per 400 g gain per week of gestation for GWG [8]. Final models were
adjusted for child’s sex and maternal age at child’s birth included as fixed coefficients and a PCR plate effect as a random batch coefficient. Allowance for other possible confounding variables such as child’s ethnic background, mode of delivery, parity, maternal smoking in pregnancy and occupation did not materially alter the estimates. Results were summarized as means and standard errors. Lists of CpG sites with differential methylation in beta values (difference >0.05) at a p value < 0.01 – a pragmatic threshold for selecting CpG sites for further study – were generated for maternal pre-pregnancy BMI, and GWG in early (from 0 to 18 weeks of pregnancy), mid (from 19 to 28 weeks of pregnancy), and late pregnancy (from 29 weeks of pregnancy onwards). False discovery rate correction for multiple testing was performed and q-values were computed by the ‘qvalue’ package in the R statistical package version 2.9.1 (R Foundation for Statistical Computing, Vienna, Austria). A false discovery rate q-value of <0.1 was considered statistically significant.

In the validation and replication analyses based on Pyrosequencing, CpG site methylation levels were also analyzed by mixed linear regression models adjusted for child’s sex and maternal age at child’s birth as fixed coefficient and PCR plate as a random batch effect as outlined above.

Ethical approval
Ethical approval for all aspects of data collection was obtained from the ALSPAC Law and Ethics Committee and the Local Research Ethics Committee in accordance with the guidelines of The Declaration of Helsinki. Written informed consent was obtained for all participants in the study.

Results
Discovery study: illumina golden gate
The discovery study population included 88 mother-offspring pairs. Participants were unrelated newborns born at term and 50% male. Mean (sd) maternal age at birth was 30.2 (3.5) years. In comparison with eligible participants for the present study, mothers included in the discovery study were older, and were less likely overweight or obese before pregnancy, but did not differ in GWG (Table 1).

Maternal pre-pregnancy BMI was not found to be associated with differentially methylated DNA at any CpG site in offspring cord blood (Additional file 1: Table S1). Early pregnancy GWG was associated with differential DNA methylation at 44 CpGs sites in offspring cord blood (p value < 0.01) (Table 2). Six out of these 44 CpG sites (located in 5 genes) had a difference in the Illumina beta value of >0.05 (MMP7_E59 p value = 1.55E-05; KCNK4_P171 p value = 4.57E-05; TRPM5_E87 p value = 0.0003; NFKB1_P496 p value = 0.0002; TRPM5_P721 p value = 0.0017; and ABCC2_E16 p value = 0.0018); of these, 4 CpG sites remained robust to correction for multiple comparison testing: MMP7_E59 (q value = 0.023), KCNK4_P171 (q value = 0.034), TRPM5_E87 (q value = 0.065), and NFKB1_P496 (q value = 0.065) (Table 2).

Greater GWG in mid pregnancy was associated with changes in methylation (difference in beta value >0.05) at one CpG site at MAP3K1_E81 (p value = 0.003); although it did not remain statistically significant after correction for multiple comparison testing (q value = 0.917) (Additional file 1: Table S2). GWG in late pregnancy was not associated with differential DNA methylation at any CpG site (all differences in beta values <0.05) (Additional file 1: Table S3).

Pyrosequencing validation study
The association of early pregnancy GWG with differential methylation at the top associated CpG site at MMP7 was validated by reanalyzing CpG site MMP7_E59 in the discovery study using Pyrosequencing. The methylation levels assayed using the GoldenGate platform did not correlate with Pyrosequenced values (R-squared = 0.005; p value = 0.508).

The two adjacent CpG sites covered in the Pyrosequenced amplicon were highly correlated with MMP7_E59 and with each other (Pearson’s correlation coefficients all >0.87; all p < 0.0001). In agreement with the discovery findings, Pyrosequencing results showed that greater GWG in early pregnancy tended to be associated with higher methylation at the MMP7_E59 CpG site, although the association did not reach statistical significance (p value = 0.302 (Table 3). Moreover, greater GWG in mid- and late pregnancy were associated with increased methylation at the MMP7_E59 CpG site (p values = 0.167 and 0.037, respectively) (Table 3). In addition, newborns of mothers that gained greater than IoM recommended weight showed higher methylation levels at the MMP7_E59 CpG site compared to those newborns of mothers with IoM recommended weight (p value = 0.080) (Table 3). Maternal GWG and IoM recommended weight categories showed similar associations with DNA methylation levels at the other 2 CpG sites evaluated at MMP7.

Replication study
The replication study population included 170 non-overlapping mother-offspring pairs from the ALSPAC cohort. Participants were unrelated newborns born at term and 51% male. Mean (sd) maternal age at birth was 28.7 (4.4) years. Compared with the discovery study sample those included in the replication study have younger mothers that were more likely overweight or obese before pregnancy, but did not differ in GWG (Table 1). Pyrosequencing results showed no association
of maternal pre-pregnancy BMI or GWG in any period of pregnancy with differential methylation at MMP7 CpG sites (all \( p \) values >0.1) (Table 4).

**Discussion**

This study examined the association of maternal pre-pregnancy BMI and GWG in different periods of pregnancy with gene-specific DNA methylation changes in offspring cord blood. Screening analysis using the Illumina GoldenGate Panel I in a discovery sample of 88 mother-offspring pairs showed greater GWG in early pregnancy (from 0 to 18 weeks) to be associated with differential methylation at 4 CpG sites at MMP7, KCNK4, TRPM5 and NFKB1 genes after correcting for multiple statistical testing. Of these four loci we undertook validation and replication using Pyrosequencing of the top associated locus at MMP7. Results of the validation study did not support evidence for an association with early pregnancy GWG with differential methylation at this locus, but was suggestive of an association with GWG in later pregnancy and for exceeded IoM recommended GWG. However, we failed to replicate these findings for this one locus in 170 non-overlapping mother-offspring pairs of the ALSPAC cohort.

The specific association of early pregnancy GWG with differential methylation at four loci is notable, since early GWG is more likely to reflect maternal fat deposition than later GWG (which will be influenced more by fetal growth) \([13]\), and so this specificity, together with the potential functional roles of these loci (see below), might support these findings as being important in developmental overnutrition. However, we were only able to undertake validation and replication studies for one, the most strongly associated loci (MMP7) and the specific early GWG association with differential methylation at that locus did not validate or replicate.

Our more significant finding in the discovery study was increased methylation of CpG sites at MMP7 gene in relation to greater GWG. Matrix metalloproteinases (MMPs) comprise a large family of structurally related

| Table 1 Characteristics of the study populations from the ALSPAC cohort |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                             | Discovery & Validation sample (n = 88) | Replication sample (n = 170) | Rest of eligible (n = 1991) |
|------------------------------|----------------------------------------|-----------------------------|----------------------------|
| Child's sex, male (%)        | 51.1                                   | 50.6                        | 49.5                       |
| Age of mother at birth, mean (sd) | 30.6 (3.3)                          | 28.7 (4.4)                  | 27.4 (5.1)                 |
| Maternal pre-pregnancy BMI (kg/m²) | Mean (sd) 22.2 (3.05)                      | 23.8 (4.1)                  | 23.1 (3.9)                 |
|                              | Normal, 18.5-24.9, (%)               | 85.9                        | 68.6                       | 73.6                       |
|                              | Underweight, < 18.5, (%)             | 1.2                         | 2.4                        | 4.8                        |
|                              | Overweight, 25.0-29.9, (%)           | 10.6                        | 20.7                       | 15.5                       |
|                              | Obese, ≥ 30, (%)                     | 2.4                         | 8.3                        | 6.1                        |
| GWG (kg/wk)                  |                                        |                             |                            |
| 0 to 18 weeks                |                                        |                             |                            |
|                              | Mean (sd)                            | 0.32 (0.17)                 | 0.31 (0.18)                | 0.30 (0.18)                |
|                              | Median                                | 0.33                        | 0.32                       | 0.31                       |
|                              | Min, Max                              | −0.33, 0.83                 | −0.22, 0.79                | −0.64, 1.31                |
| 19-28 weeks                  |                                        |                             |                            |
|                              | Mean (sd)                            | 0.55 (0.17)                 | 0.54 (0.16)                | 0.53 (0.18)                |
|                              | Median                                | 0.55                        | 0.53                       | 0.53                       |
|                              | Min, Max                              | 0.22, 1.00                  | 0.14, 0.96                 | −0.18, 1.45                |
| 29 weeks onwards             |                                        |                             |                            |
|                              | Mean (sd)                            | 0.49 (0.18)                 | 0.47 (0.20)                | 0.46 (0.21)                |
|                              | Median                                | 0.47                        | 0.45                       | 0.45                       |
|                              | Min, Max                              | −0.02, 0.95                 | 0.03, 1.04                 | −0.54, 1.22                |
| IoM categories, (%)          |                                        |                             |                            |
|                              | Recommended                           | 36.6                        | 37.3                       | 36.1                       |
|                              | Less than recommended                 | 34.1                        | 31.9                       | 35.8                       |
|                              | More than recommended                 | 29.3                        | 30.8                       | 28.1                       |

\(^4\) Subjects initially included in the discovery study (n = 88) failed in the validation study.

\(^5\) Participants of the ALSPAC cohort with available cord blood DNA.
| Chr | Gene name | CpG site | Position | Coef. (se) | p value | q value |
|-----|-----------|----------|----------|------------|---------|---------|
| 11  | Matrix metallopeptidase 7 | MMP7_E59 | 101906629 | 0.072 (0.016) | 1.55E-05 | 0.023 |
| 11  | Potassium channel, subfamily K, member 4 | KCNK4_P171 | 63815280 | 0.060 (0.014) | 4.57E-05 | 0.034 |
| 19  | Janus kinase 3 | JAK3_P1075 | 17820875 | 0.034 (0.008) | 7.13E-05 | 0.036 |
| 11  | Transient receptor potential cation channel, subfamily M, member 5 | TRPM5_E87 | 2400764 | 0.072 (0.020) | 0.0003 | 0.065 |
| 12  | Protein tyrosine phosphatase, non-receptor type 6 | PTPN6_E171 | 6926172 | 0.042 (0.011) | 0.0003 | 0.065 |
| 4   | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | NFKB1_P496 | 103641022 | 0.058 (0.016) | 0.0002 | 0.065 |
| 1   | Absent in melanoma 2 | AIM2_E208 | 157313063 | 0.015 (0.004) | 0.0003 | 0.065 |
| 17  | Ecotropic viral integration site 2A | EV2A_E420 | 2667243 | 0.039 (0.010) | 0.0002 | 0.065 |
| 17  | Septin 9 | SEPT9_P58 | 72827686 | 0.034 (0.010) | 0.0005 | 0.077 |
| 11  | Interleukin 16 | IL16_P93 | 79262162 | 0.037 (0.011) | 0.0005 | 0.077 |
| 9   | PALM2-AKAP2 protein | PALM2_AKAP2_P183 | 111582227 | 0.025 (0.007) | 0.0005 | 0.077 |
| 20  | DNA (cytosine-5-)-methyltransferase 3 beta | DNMT3B_P352 | 30813500 | 0.040 (0.012) | 0.0005 | 0.077 |
| 11  | Tumor susceptibility gene 101 | TSG101_P139 | 101532577 | 0.078 (0.025) | 0.0018 | 0.148 |
| 11  | Solute carrier family 22 (organic cation transporter), member 18 | SLC22A18_P216 | 2877311 | 0.032 (0.011) | 0.0021 | 0.155 |
| 11  | Transient receptor potential cation channel, subfamily M, member 5 | TRPM5_P721 | 2401572 | 0.053 (0.017) | 0.0017 | 0.148 |
| 10  | ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | ABCC2_E16 | 101532577 | 0.027 (0.008) | 0.0021 | 0.155 |
| 12  | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | KRAS_E82 | 25295039 | 0.042 (0.014) | 0.0021 | 0.155 |
| 11  | Tumor susceptibility gene 101 | TSG101_P139 | 18505204 | 0.045 (0.015) | 0.0022 | 0.155 |
| 11  | Solute carrier family 22 (organic cation transporter), member 18 | SLC22A18_P216 | 18505204 | 0.045 (0.015) | 0.0022 | 0.155 |
| 20  | v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) | SRC_P164 | 35406338 | 0.051 (0.017) | 0.0021 | 0.155 |
| 6   | Major histocompatibility complex, class II, DO beta | HLA_DOB_P1114 | 32893876 | 0.014 (0.004) | 0.0027 | 0.177 |
| 17  | Biglycan | BGN_P333 | 15241327 | 0.027 (0.009) | 0.0030 | 0.181 |
| 2   | Interleukin 1, beta | IL1B_P829 | 113311656 | 0.029 (0.009) | 0.0030 | 0.181 |
| 11  | Cathepsin D (lysosomal aspartyl peptidase) | CTSD_P726 | 1742524 | 0.033 (0.011) | 0.0034 | 0.192 |
| 7   | Carboproteinase A4 | CPA4_P961 | 12971926 | 0.020 (0.007) | 0.0035 | 0.192 |
| 22  | Breakpoint cluster region (BCR) | BCR_P346 | 21852130 | 0.024 (0.007) | 0.0036 | 0.192 |
| 16  | PYD and CARD domain containing | PYCARD_E87 | 31121665 | 0.023 (0.008) | 0.0038 | 0.192 |
| 17  | Homeo box B2 | HOXB2_P99 | 43977490 | 0.040 (0.014) | 0.0038 | 0.192 |
| 17  | v-crk sarcoma virus CT10 oncogene homolog (avian) | CRK_P721 | 1307015 | 0.043 (0.015) | 0.0039 | 0.192 |
| 22  | Seizure related 6 homolog (mouse-like) | SEZ6L_P299 | 24951818 | 0.031 (0.011) | 0.0044 | 0.208 |
| 19  | Kallikrein 11 | KLK11_P103 | 56232625 | 0.022 (0.008) | 0.0046 | 0.210 |
| 17  | ELK1, member of ETS oncogene family | ELK1_E156 | 47394808 | 0.025 (0.009) | 0.0058 | 0.255 |
| 2   | CDC-like kinase 1 | CLK1_P538 | 201438205 | 0.036 (0.013) | 0.0064 | 0.263 |
| 6   | Solute carrier family 22 (organic cation transporter), member 2 | SLC22A2_P109 | 160600058 | 0.021 (0.008) | 0.0064 | 0.263 |
| 19  | Apolipoprotein C-II | APOC2_P377 | 50140706 | 0.015 (0.006) | 0.0067 | 0.263 |
| 17  | Dyskeratosis congenita 1, dyskerin | DKC1_P276 | 153644068 | 0.030 (0.011) | 0.0066 | 0.263 |
| 20  | v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) | SRC_P297 | 35406205 | 0.025 (0.009) | 0.0080 | 0.300 |
Table 2 List of CpG sites with differential methylation at a p value < 0.01 in newborn cord blood DNA per 400 g of weight gain/week in early pregnancy (from 0 to 18 weeks), the ALSPAC cohort (n = 88) (Continued)

| N  | Gene name         | Chromosome | Gene Position | p-value | q-value | MAF | MAF 1  |
|----|-------------------|------------|--------------|---------|---------|-----|--------|
| 10 | N-acetyltransferase 2 | NAT2_P11   | 18293024     | 0.012   | 0.0047  | 0.30 | 0.30   |
| 8  | PTK2 protein tyrosine kinase 2 | PTK2_P735 | 142081249     | 0.022   | 0.0085  | 0.32 | 0.32   |
| 1  | CD34 antigen      | CD34_P339 | 206151645     | 0.021   | 0.0092  | 0.33 | 0.33   |
| 4  | Interleukin 8     | IL8_P83   | 74825056      | 0.051   | 0.0098  | 0.33 | 0.33   |
| 11 | Progesterone receptor | PGR_P790  | 100507255     | 0.019   | 0.0096  | 0.33 | 0.33   |

aChromosome. bChromosomal position based on NCBI human reference genome assembly Build 36.1.

Probes shown in bold displayed >5% difference in methylation.

MMP7 methylation of MMP7 is down regulated in obesity [29,30]. These findings were not undertaken for other CpG sites that were identified as being differentially methylated in relation to greater GWG and located in genes KCNK4, TRPM5 and NFKB1. However, these three identified genes may be worthy of further exploration. KCNK4 encodes for a potassium channel, subfamily K, member 4 known as Trek/TRAoAK channels that has been described to be expressed in the central nervous system, modulate neuronal activity, brain metabolism and have a role in neuroprotection [31,32]. Knockout animal models have shown a role for Trek/TRAoAK channels in behaviour, learning and memory [33,34]. Interestingly, greater maternal pre-pregnancy BMI and GWG have been shown to be associated with offspring impaired cognition and behavioural problems later in life, including in the ALSPAC study [3,4]. In addition, TRPM5 encodes for a thermo-sensitive TRP (transient receptor potential) channel that is expressed in pancreatic β-cells and could predominantly contribute to pancreatic functions [35]. In humans, genetic variation in TRPM5 has been reported to be likely associated with pre-diabetic phenotypes and contribute to the development of type 2 diabetes mellitus [36]. Furthermore, TRPM5 knockout mice exhibit impaired glucose clearance resulting from reductions in insulin secretion [37,38]. This evidence from animal studies is in accordance with our results showing increased methylation of TRPM5 CpG sites in relation to greater maternal GWG; this may in turn result in lower expression of TRPM5 and, thus, perturbed insulin metabolism and increased risk of diabetes in the offspring as it has been previously suggested [39]. Finally, NFKB1 encodes for nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, which is responsible for activation of transcription of genes involved in immune responses, inflammation or cell proliferation [40]. Genetic variation in NFKB1 gene has been reported to be associated with a range of immune-mediated diseases such as atopy, asthma and related phenotypes [41], which are also related to maternal obesity and GWG [42,43]. Therefore, DNA methylation changes at these three loci highlighted in the screening analysis appear to have clear functional relevance to pathways implicated in development of adverse phenotypes in offspring linked to maternal obesity and GWG and therefore deserve further investigation.

The strengths of this study are the prospective design and that potential confounding factors were taken into account in the analyses. Further, we evaluated the association of pre-pregnancy BMI and GWG in distinctive periods of pregnancy with offspring cord blood DNA methylation patterns. To our knowledge no previous human studies have examined these associations, yet these maternal exposures have been shown to be related to later offspring outcomes and it has been suggested these associations may be mediated by epigenetic mechanisms [8,13,14]. The ability to examine associations of different pregnancy periods of GWG is a particular strength as our expectation would be that GWG in early pregnancy would be specifically associated with outcomes and we were able to test that here.
However, the study has some limitations. Firstly, DNA methylation changes were assessed in cord blood, which limits to know how identified changes could translate to potential target tissues. However, DNA methylation patterns are largely conserved across tissues suggesting that for population based epidemiological studies methylation markers from easily accessible surrogate tissues could be used as a proxy for methylation in target tissues [44]. Because cell count information was not available we cannot rule out the potential impact of cell heterogeneity on present findings. Secondly, limited sample size of the discovery study population may have resulted in low statistical power to detect true differences in DNA methylation patterns and false positives could have occurred. In addition, lack of correlation of methylation levels in \textit{MMP7} CpG sites measured with the GoldenGate array and Pyrosequencing limits the conclusions that can be drawn from the present validation and replication studies. Thirdly, smaller effect sizes in DNA methylation were found and biological significance in terms of changes in gene expression is unknown. However, it may be a general phenomenon in complex diseases and phenotypes, where methylation at any given CpG island or specific CpG sites in affected versus unaffected individuals may vary by less than 10%, indeed they have been reported in many other human epigenetic studies. Moreover, for some genes, evidence exists that a small change in the level of DNA methylation, especially in the lower range, can dramatically alter gene expression levels [45]. We opted not to consider differentially methylated site below a threshold of 5% due to the limitations inherent in interpreting biological significance, although this cut off may have limited our findings. Fourthly, the Illumina GoldenGate Panel I was used for screening of DNA regions differently methylated in DNA cord blood. The CpG sites included in this array are based on their functional relevance to tumor development and cancer processes, which only in some aspects can be related to fetal development (such as cell proliferation). However, this array was not designed for

### Table 3 Validation study: associations of maternal pre-pregnancy BMI and gestational weight gain (GWG) with \textit{MMP7} CpG sites methylation levels in newborn cord blood DNA

|                  | \textit{CpG1} | \textit{CpG2} | \textit{CpG3} (E59) | Mean of 3 CpGs |
|------------------|--------------|--------------|--------------------|---------------|
|                  | Coef$^a$ (se) | p value      | Coef$^a$ (se)      | p value       | Coef$^a$ (se) | p value | Coef$^a$ (se) | p value |
| Pre-pregnancy BMI | 0.80 (0.70)  | 0.250        | 1.15 (0.78)        | 0.143         | 1.22 (0.82)  | 0.139   | 1.06 (0.75)  | 0.158   |
| GWG 0 to 18 wks. | 0.80 (1.99)  | 0.686        | 1.52 (2.27)        | 0.505         | 2.44 (2.36)  | 0.302   | 1.59 (2.15)  | 0.461   |
| GWG 19 to 28 wks.| 0.96 (1.73)  | 0.580        | 2.89 (1.95)        | 0.141         | 2.83 (2.04)  | 0.167   | 2.23 (1.86)  | 0.232   |
| GWG 29 wks. onwards | 2.38 (1.57) | 0.133        | 3.25 (1.79)        | 0.071         | 3.90 (1.85)  | 0.037   | 3.17 (1.69)  | 0.062   |
| GWG IoM categories |             |              |                    |               |             |        |            |        |
| Recommended      | 2.03 (1.74)  | 0.246        | 0.18 (2.00)        | 0.930         | 0.38 (2.09)  | 0.853   | 0.86 (1.90)  | 0.649   |
| Less than recommended | 3.35 (1.79) | 0.063        | 3.13 (2.06)        | 0.131         | 3.81 (2.16)  | 0.080   | 3.43 (1.96)  | 0.082   |

$^a$Regression coefficient using linear mixed models. For pre-pregnancy BMI (kg/m2) estimated changes per 1 SD change and for GWG estimated changes per additional 400 g/week.
All models adjusted for child’s sex and maternal age and the inclusion of a PCR plate random batch effect.

### Table 4 Replication study: associations of maternal pre-pregnancy BMI and gestational weight gain (GWG) with \textit{MMP7} CpG sites methylation levels in newborn cord blood DNA (n = 170)

|                  | \textit{CpG1} | \textit{CpG2} | \textit{CpG3} (E59) | Mean of 3 CpGs |
|------------------|--------------|--------------|--------------------|---------------|
|                  | Coef$^a$ (se) | p value      | Coef$^a$ (se)      | p value       | Coef$^a$ (se) | p value | Coef$^a$ (se) | p value |
| Pre-pregnancy BMI | −0.03 (0.57) | 0.952        | −0.44 (0.66)       | 0.501         | −0.48 (0.69)  | 0.486   | −0.31 (0.62)  | 0.613   |
| GWG 0 to 18 wks. | −0.34 (1.28) | 0.791        | −0.62 (1.46)       | 0.671         | −0.76 (1.55)  | 0.621   | −0.58 (1.39)  | 0.674   |
| GWG 19 to 28 wks.| −0.25 (1.45) | 0.863        | −1.04 (1.65)       | 0.528         | −0.46 (1.75)  | 0.790   | −0.60 (1.56)  | 0.702   |
| GWG 29 wks. onwards | 0.57 (1.16) | 0.622        | 0.42 (1.33)        | 0.751         | 0.01 (1.41)  | 0.994   | 0.34 (1.26)  | 0.787   |
| GWG IoM categories |             |              |                    |               |             |        |            |        |
| Recommended      | 0 [Ref]      | 0 [Ref]      | 0 [Ref]            | 0 [Ref]       | 0 [Ref]     | 0 [Ref] |            |        |
| Less than recommended | −2.00 (1.37) | 0.144        | −1.54 (1.56)       | 0.323         | −1.62 (1.65)  | 0.329   | −1.71 (1.48)  | 0.249   |
| More than recommended | −1.85 (1.39) | 0.185        | −2.07 (1.59)       | 0.195         | −2.24 (1.68)  | 0.185   | −2.04 (1.51)  | 0.177   |

$^a$Regression coefficient using linear mixed models. For pre-pregnancy BMI (kg/m2) estimated changes per 1 SD change and for GWG estimated changes per additional 400 g/week.
All models adjusted for child’s sex and maternal age and the inclusion of a PCR plate random batch effect.
epigenome-wide analyses, and methylation changes at other loci in genes relevant to maternal GWG may have been overlooked. The use of the 450 k Beadchip that offers greatly improved genomic coverage over the GoldenGate and 27 k platforms is warranted in future studies. Finally, we were only able to take forward the top associated loci at MMP7 for validation and replication, which limits the interpretation of results for the other three loci that were identified as being associated with GWG in early pregnancy. Given the likely functional relevance of these and the specificity of association with early GWG we feel that further study of these loci is warranted.

Conclusions
We found that greater GWG, specifically in early pregnancy, was associated with increased methylation at 4 CpG sites at MMP7, KCNK4, TRPM5 and NFKB1 genes in offspring cord blood DNA. These four loci were all potentially functionally relevant but we were only able to take the top associated locus at MMP7 forward for validation using Pyrosequencing and replication in non-overlapping mother-offspring pairs. The specific association with GWG in early pregnancy for that one site was not statistically significantly validated and it did not replicate. Given this is the first study we are aware of to examine these associations and our findings might reflect limited statistical power, we advocate further exploration of identified loci in larger studies and the study of genome-wide DNA methylation data.

Additional file

Additional file 1: Supplementary material for DNA methylation signatures in cord blood associated with maternal gestational weight gain: results from the ALSPAC cohort.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
DAL and CLR: obtained funding for the study and initially designed it. EM and CLR: developed the study aims. EM and AG: conducted the experiments, under the supervision of CLR. EM: performed the statistical analyses and wrote the first draft of the manuscript. EM, DAL and CLR participated in the interpretation of data. All authors help to draft the manuscript, and read and approved the final manuscript.

Acknowledgements
Prof Kate Tilling and Drs Abigail Fraser and Corrie Macdonald-Wallis are acknowledged for their contribution to derivation of the gestational weight gain trajectories, and Prof Seif Shaheen for his contributing to funding the generation of Illumina GoldenGate methylation data. Dr Catherine Potter is thanked for her assistance in shaping the manuscript. We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses.

Funding
The UK Medical Research Council and the Wellcome Trust (Grant ref: 092731) and the University of Bristol provide core support for ALSPAC. Obstetric data abstraction and derivation of maternal pregnancy variables, including GWG, were supported by grants from the US NIH (R01 DK077659) and UK Wellcome Trust (WT087997MA). AG, DAL and CR work in a Unit that receives funding from the University of Bristol and UK Medical Research Council (MC_UU_12013/2 and MC_UU_12013/5). EM was supported by a Rio Hortega fellowship (CM09/100090) from the Spanish Ministry of Science and Innovation. This publication is the work of the authors and Prof Caroline Relton will serve as guarantor for the contents of this paper.

Author details
1Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, NE1 3BZ, Tyne and Wear, UK. Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Catalonia, Spain. 2Hospital del Mar Medical Research Institute (IMIM), Barcelona, Catalonia, Spain. 3CIBER in Epidemiology and Public Health (CIBERESP), Barcelona, Spain. 4MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK. 5School of Social and Community Medicine, University of Bristol, Bristol, UK.

Received: 11 December 2013 Accepted: 10 April 2014
Published: 2 May 2014

References
1. Ludwig DS, Currie LJ: The association between pregnancy weight gain and birthweight: a within-family comparison. *Lancet* 2010, 376:984–990.
2. Monte S, Valenti O, Giorgio E, Renda E, Hyseni E, Faraci M, De Domenico R, Di Prima FA: Maternal weight gain during pregnancy and neonatal birth weight: a review of the literature. *J Perinat Med* 2011, 37:27–30.
3. Rodríguez A, Miettunen J, Henriksson TB, Olsen J, Obel C, Taanila A, Ebeling H, Linnet KM, Moilanen I, Järvelin MR: Maternal adiposity prior to pregnancy is associated with ADHD symptoms in offspring: evidence from three prospective pregnancy cohorts. *Int J Obes* 2008, 32:550–557.
4. Gage SH, Lawlor DA, Tilling K, Fraser A: Associations of maternal weight gain in pregnancy with offspring cognitive development in childhood and adolescence: findings from the Avon Longitudinal Study of Parents and Children. *Am J Epidemiol* 2013, 177:402–410.
5. Oken E, Taveras EM, Kleinman KP, Rich-Edwards JW, Gillman MW: Gestational weight gain and child adiposity at age 3 years. *Am J Obstet Gynecol* 2007, 196:322.e1–8.
6. Morera P, Padez C, Mouaou-Carvalhal I, Rosado V: Maternal weight gain during pregnancy and overweight in Portuguese children. *Int J Obes* (Lond) 2007, 31:508–514.
7. Wotniak BH, Shujs, J, Butts S, Settler H: Gestational weight gain and risk of overweight in the offspring at age 7 y in a multicenter, multiethnic cohort study. *Am J Clin Nutr* 2008, 87:1818–1824.
8. Fraser A, Tilling K, Macdonald-Wallis C, Sattar N, Bron MJ, Benfield L, Ness A, Deanfield J, Hingorani A, Nelson SM, Smith GD, Lawlor DA: Association of maternal weight gain in pregnancy with offspring obesity and metabolic and vascular traits in childhood. *Circulation* 2010, 121:2557–2564.
9. Oken E, Rifas-Shiman SL, Field AE, Frazier AL, Gillman MW: Maternal gestational weight gain and offspring weight in adolescence. *Obstet Gynecol* 2008, 112:999–1006.
10. Mamun AA, O’Callaghan M, Callaway L, Williams G, Najman J, Lawlor DA: Associations of gestational weight gain with offspring body mass index and blood pressure at 21 years of age: evidence from a birth cohort study. *Circulation* 2009, 119:1720–1727.
11. Hochner H, Friedlander Y, Calderon-Margalit R, Meiner V, Sagi Y, Avigl-Tsadok M, Burger A, Savitsky B, Sisovsck DS, Manor O: Associations of maternal prepregnancy body mass index and gestational weight gain with adult offspring cardiometabolic risk factors: the Jerusalem Perinatal Family Follow-up Study. *Circulation* 2012, 125:1381–1389.
12. Lahtinen J, Jääskeläinen A, Hartikainen AL, Sovio U, Vääräsmäki M, Poussa A, Kaakinen M, Järvelin MR: Maternal weight gain during the first half of pregnancy and offspring obesity at 16 years: a prospective cohort study. *BJOG* 2012, 119:716–723.
13. Lawlor DA, Relton C, Sattar N, Nelson SM: Maternal adiposity—a determinant of perinatal and offspring outcomes? *Nat Rev Endocrinol* 2012, 8:679–688.
14. Lawlor DA: The Society for Social Medicine John Pemberton Lecture, Developmental overnutrition—an old hypothesis with new importance? Int J Epidemiol 2011, 2013:24(7–29).

15. Guérard F, Deshaies Y, Clainfonde K, Kalp JG, Marceau P, Vohl MC: Differential methylation in glucoregulatory genes of offspring born before vs. after maternal gastrointestinal bypass surgery. Proc Natl Acad Sci U S A 2013, 110:1439–1444.

16. Guérard F, Tcherenoff A, Deshaies Y, Clainfonde K, Kalp JG, Marceau P, Vohl MC: Methylation and expression of immune and inflammatory genes in the offspring of bariatric bypass surgery patients. J Obes 2013, 2013:492170.

17. Liu X, Chen Q, Tsai HJ, Wang G, Hong X, Zhou Y, Zhang C, Liu C, Liu R, Wang H, Zhang S, Yu Y, Mestan RK, Pearson C, Oltans P, Zuckerman B, Wang X: Maternal preconception body mass index and offspring cord blood DNA methylation: Exploration of early life origins of disease. Environ Mol Mutagen 2014, 52:223–230.

18. Borengasser SJ, Zhong Y, Kang P, Lindsey F, Ronis MJ, Badger TM, Gomez-Acevedo H, Shankar K: Maternal obesity enhances white adipose tissue differentiation and alters genome-scale DNA methylation in male rat offspring. Endocrinology 2013, 154:111–421.

19. Yang QY, Liang JF, Rogers CJ, Zhao XK, Zhu MJ, Du M: Maternal obesity induces epigenetic modifications to facilitate zfp423 expression and enhance adipogenic differentiation in fetal mice. Diabetes 2013, 62:3727–3735.

20. Boyd A, Golding J, Henderson J, Macleod J, Lawlor DA, Fraser A, Henderson J, Macleod J, Molloy L, Ness A, Ring S, Davey Smith G: Cohort Profile: the children of the 90’s—the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol 2013, 42:111–117.

21. Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, Henderson J, Macleod J, Molloy L, Ness A, Ring S, Nelson SM, Lawlor DA: Cohort profile: the Avon Longitudinal Study of Parents and Children: ALSpac mothers cohort. Int J Epidemiol 2013, 42:99–110.

22. Belton CL, Groom A, St Pouscain B, Sayers AE, Swan DC, Emberton ND, Pearce MS, Ring SM, Northstone K, Tobias JH, Tiakalo J, Ness AR, Shaheen SO, Davey Smith G: DNA methylation patterns in cord blood DNA and body size in childhood. PLoS One 2012, 7:e31821.

23. IOM (Institute of Medicine) and NRC (National Research Council): Weight Gain During Pregnancy. In Examining the Guidelines: Edited by Kathleen M, Rasmussen YM, Yaktine AL. Washington, DC: The National Academies Press; 2009.

24. Office of Population and Census Statistics: Maternal obesity enhances white adipose tissue differentiation and alters genome-scale DNA methylation in male rat offspring. Endocrinology 2013, 154:111–421.

25. WHO: Obesity: Preventing and managing the global epidemic. Geneva: World Health Organization; 2000.

26. OECD: Obesity, physical inactivity and sedentary behavior. OECD Health Working Papers Series 2012, 1–62.

27. White HE, Durston VJ, Harvey JF, Cross NC: Quantitative analysis of SNRPN (correction of SRPN) gene methylation by pyrosequencing as a diagnostic test for Prader-Willi syndrome and Angelman syndrome. Clin Chem 2006, 52:1005–1013.

28. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463–516.

29. Maquie E, Munaut C, Colige A, Collen D, Lijnen HR: Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 2002, 51:1093–1101.

30. Chavey C, Mai B, Monthoulou MN, Bonfous S, Anglard P, Van Obberghen E, Tartare-Deckert S: Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem 2003, 278:11888–11896.

31. Talley EM, Solorzano G, Lee K, Kim D, Bayliss DA: Csn distribution of members of the two-pore-domain (KCNK) potassium channel family. J Neurosci 2001, 21:4941–7955.

32. Judge SJ, Smith PJ: Patents related to therapeutic activation of K (ATP) and K (2P) potassium channels for neuroprotection: ischemic/hypoxic/anoxic injury and general anesthetics. Expert Opin Ther Pat 2009, 19:333–460.

33. Deng PY, Xiao Z, Yang C, Rojanathammanee L, Grisanti L, Watt J, Geiger JD, Liu R, Porter JE, Lee S: GABA (B) receptor activation inhibits neuronal excitability and spatial learning in the entorhinal cortex by activating TREK-2 K + channels. Neuroph 2009, 63:230–243.

34. Mirkovic K, Palmsheimer J, Lesage F, Widman K: Behavioral characterization of mice lacking TREK channels. Front Behav Neurosci 2012, 6:50.

35. Uchida K, Tominaga M: The role of thermosensitive TRP (transient receptor potential) channels in insulin secretion. Endocr J 2011, 58:1021–1028.

36. Ketetser C, Müssig K, Heni M, Dudiadka K, Randrianarisoa E, Wagner R, Machicao F, Stefan N, Holst JJ, Fritsche A, Häring HU, Staiger H: Genetic variation within the TRPM5 locus associates with prediabetic phenotypes in subjects at increased risk for type 2 diabetes. Metabolism 2011, 60:325–1333.

37. Colson B, Schraemenn A, Lemaine K, Quinteens R, Van Lommel L, Segal A, Dusaiangk T, Talatena K, Voets T, Margoliske RF, Kokashvili Z, Gilson P, Nillius B, Schult FC, Verneken R: Loss of high-frequency glucose-induced Ca2+ oscillations in pancreatic islets correlates with impaired glucose tolerance in Trpm5−/− mice. Proc Natl Acad Sci U S A 2010, 107:5208–5213.

38. Briat JSR, Montell-Zoller MK, Ingenbrandt CS, Fleig A, Penner R, Enklaar T, Zabel BM, Pratt D: TRPM5 regulates glucose-stimulated insulin secretion. Pflug Arch 2010, 460:596–596.

39. Armitage JA, Khan IY, Taylor PD, Nathaniel PW, Poston L: Developmental programming of the metabolic syndrome by maternal nutritional imbalance: how strong is the evidence from experimental models in mammals? J Physiol 2004, 561:355–377.

40. Baldwin AS Jr: Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 2001, 107:3–4.

41. Smyth DJ, Howson JM, Payne F, Maier LM, Bailey R, Holland K, Lowe CE, Cooper JD, Huline JS, Vella A, Dahlman I, LAM AC, Nutland S, Walker NM, Twells RC, Todd JA: Analysis of polymorphisms in 16 genes in type 1 diabetes that have been associated with other immune-mediated diseases. BMC Med Genet 2006, 7:20.

42. Harpsee MC, Basit S, Rager P, Wohlfahrt J, Benn CS, Nøhr EA, Linneberg A, Zabel BM, Pratt D: TRPM5 regulates glucose-stimulated insulin secretion. Pflug Arch 2010, 460:596–596.

43. Ma B, Willker EH, Willis-Owen SA, Byun HM, Wong KC, Motta V, Baccarelli AA, Schwartz J, Cookson WD, Khabbaz K, Mittleman MA, Moffatt MF, Liang L: Predicting DNA methylation level across human tissues. Nucleic Acids Res 2014, 42:515–525.

44. Lillycrop KA, Phillips ES, Torens C, Hanson MA, Jackson AA, Burdge GC: Feeding pregnant rats a protein-restricted diet persistently alters the methylation of specific cytosines in the hepatic PPAR α promoter of the offspring. Br J Nutr 2008, 100:278–282.